Who makes TMC435 gelatin capsule?

TMC435 gelatin capsule is developed by Tibotec Pharmaceuticals, Ireland.

What development phase is TMC435 gelatin capsule in?

TMC435 gelatin capsule is in Phase 1.

Last reviewed 2026-05-13 · How we verify

TMC435 gelatin capsule

Tibotec Pharmaceuticals, Ireland · Phase 1 active Small molecule

At a glance

Generic name	TMC435 gelatin capsule
Sponsor	Tibotec Pharmaceuticals, Ireland
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TMC435 gelatin capsule CI brief — competitive landscape report
TMC435 gelatin capsule updates RSS · CI watch RSS
Tibotec Pharmaceuticals, Ireland portfolio CI